
# Neuronox®

## The First Choice of Botulinum Toxin Type A

Purified Botulinum Toxin Type A Complex

Medytox

The First Choice of
Botulinum Toxin Type A


Medytox

Neuronox®

Purified Botulinum Toxin Type A Complex

## Proven Efficacy & Safety

The efficacy and safety of Neuronox® is proved and verified to be comparable to Botox (Allergan Inc.)'s in clinical studies.

## Global Product

Global Product, Neuronox® has been sold in over 50 countries, since its first launch in 2004. Neuronox® is being sold worldwide under different brand names, such as Sias®, Cunox®, Botulift® and Meditoxin®.

## Various choices

Neuronox® consists of 50, 100 and 200 units, offering various choices according to the application. It is easier to use for doctors and more economical for patients.

# Proven Efficacy & Safety

The efficacy and the safety of Neuronox® are proved to be comparable to Botox(Allergan Inc.)'s in various clinical studies.

**1. Glabellar Frown Lines**

Comparative clinical study for glabellar frown lines[1)] with Neuronox® vs. Botox®: **Comparable Efficacy and Safety**

··· Glabellar lines improvement rate at maximum frown (PP set)

1:1 clinical conversion ratio




**Methodology** Multicenter, double-blind, randomized, parallel design, active-controlled phase III clinical study. Each patient was randomly assigned to receive 20U (0.5ml) of either Neuronox®(n=142) or Botox® (n=146). The total dose was distributed over 5 injection points into corrugators and procerus. Results of the treatment were evaluated at 4-week intervals: up to 16 week.

**Subjects** 314 healthy adult patients (aged between 20 to 65) with moderate or severe glabellar lines at maximum frown. *four-point scale (0=none, 1=mild, 2=moderate, 3=severe)

**Results** Neuronox® was proved its non-inferiority to Botox® in this clinical study.Therefore, Neuronox® is effective and safe for the treatment of glabellar frown lines.

SAFETY

In this study, 26.92% of patients treated with Neuronox® and 22.29% of patients received Botox® experienced adverse events. There was no statistical difference in the incidence and the severity of adverse events between two products (p=0.3416).

1) Data on file. Medytox Inc.



Neuronox®


Comparative clinical study for glabellar frown lines with Neuronox® vs. Botox®: **More satisfaction**

··· Patient satisfaction with the results (PP set)

1:1 clinical conversion ratio




··· Before & After with Neuronox®




Photo taken at maximum frown before treatment with Neuronox® and after 14 days. Individual results may vary.

# Proven Efficacy & Safety

The efficacy and the safety of Neuronox® are proved to be comparable to Botox(Allergan Inc.)'s in various clinical studies.

### 2. Essential Blepharospasm

Comparative clinical study for essential blepharospasm[2] with Neuronox® vs. Botox®: **Comparable Efficacy and Safety**


**Methodology** Multi-center, double blinded, randomized, active controlled, parallel designed, phase Ⅲ clinical study

**Subjects** 60 patients diagnosed as essential blepharospasm (Neuronox® n=31 / Botox® n=29)

**Results** The efficacy of Neuronox® was not inferior to Botox® in this clinical study. No difference was noted in the frequency of adverse event. Neuronox® can be safely used as an alternative to Botox® treatment at 1:1 equivalence.

2) Yoon JS et al. Double-Blind, Randomized, Comparative Study of Meditoxin® Versus Botox® in the Treatment of Essential Blspharospasm. Korean Journal of Ophthalmology 2009;23:137-141



Neuronox®


### 3. Equinus Deformity in Cerebral Palsy

Comparative clinical study for equines deformity in cerebral palsy[3] with Neuronox® vs. Botox®: **Comparable Efficacy and Safety**




**Methodology** Multi-center, double blinded, randomized, active controlled, parallel designed, phase Ⅲ clinical study

**Subjects** 119 pediatric patients diagnosed as spastic cerebral palsy with equinus foot deformity (Neuronox® n=60 / Botox® n=59)

**Results** Neuronox® was not inferior to Botox® in this clinical study. No differences were noted in the frequency of adverse event. Neuronox® can be safely used as an alternative to Botox® treatment.

3) Moon Suk Bang et al. Meditoxin® Versus Botox® for spastic equinus gait in children with cerebral palsy Double-Blind, Randomized, Controlled multicenter clinical trial Developmetn Medicine & Child Neurology 2010.

# Global Product

Neuronox® is registered in 25 countries including Brazil, India, Hong Kong, and Lebanon, and is in the process of registration in other 30 countries.



Registered countries
Registration in progress

**Registered countries***

| | | | | |
|---|---|---|---|---|
| AZERBAIJAN | COSTARICA | HONGKONG | KYRGYZSTAN | PHILIPPINES |
| BOLIVIA | DOMINICA REP | INDIA | LEBANON | THAILAND |
| BRAZIL | EL SALVADOR | IRAN | NICARAGUA | UKRAINE |
| CHILE | GEORGIA | KAZAKHSTAN | PANAMA | UZBEKISTAN |
| COLOMBIA | GUATEMALA | KOREA | PERU | VIETNAM |





# Various Choice of products

Neuronox® offers various choices according to the application. It is easier to use for doctors and more economical for patients.

| Product |  Neuronox® 50U |  Neuronox® 100U |  Neuronox® 200U |
|---|---|---|---|
| Manufacturer | Medytox Inc. | Same as left | Same as left |
| Drying Method | Freeze-dried | Same as left | Same as left |
| Potency per vial | 50U | 100U | 200U |
| Composition | 50Units of Clostridium botulinum toxin type A complex | 100Units of Clostridium botulinum toxin type A complex | 200Units of Clostridium botulinum toxin type A complex |
| | 0.25mg of human serum albumin | 0.5mg of human serum albumin | 1.0mg of human serum albumin |
| | 0.45mg of sodium chloride | 0.9mg of sodium chloride | 1.8mg of sodium chloride |

| Dilution Information | Diluent Added (0.9% sodium chloride) | Resulting Dose Units (Units /0.1mL) | Diluent Added (0.9% sodium chloride) | Resulting Dose Units (Units /0.1mL) | Diluent Added (0.9% sodium chloride) | Resulting Dose Units (Units /0.1mL) |
|---|---|---|---|---|---|---|
| | 0.5mL | 10.0U | 1.0mL | 10.0U | 1.0mL | 20.0U |
| | 1.0mL | 5.0U | 2.0mL | 5.0U | 2.0mL | 10.0U |
| | 2.0mL | 2.5U | 4.0mL | 2.5U | 4.0mL | 5.0U |
| | 4.0mL | 1.25U | 8.0mL | 1.25U | 8.0mL | 2.5U |


The First Choice of Botulinum Toxin Type A

Purified Botulinum Toxin Type A Complex


www.medytox.com

MT-11010